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Ethical Issues Regarding the Donation and Source of Cells
for Tissue Engineering: A European Focus Group Study
Anke J.M. Oerlemans, M.A., M.Sc.,1 Paul P. van den Berg, M.D., Ph.D.,2
Evert van Leeuwen, Ph.D.,1 and Wim J.M. Dekkers, M.D., Ph.D.1
This article is part of the EuroSTEC project, which aims at developing tissue engineering-based treatments for
structural disorders present at birth. EuroSTEC is positioned at the intersection of three areas with their own ethical
issues: (1) regenerative medicine, (2) research with pregnant women and fetuses, and (3) research with neonates.
Because of the link between these three areas in this project, one can expect to be confronted with new ethical
challenges. To be able to respond adequately and timely to current and possible future ethical issues, a prospective
and anticipatory ethical analysis is essential. To obtain a first impression of the ethical issues that might arise
during the different phases of the project, a Delphi method was used. On the basis of the results of two previous
rounds of questionnaires, two topics were selected for discussion in focus groups: ethical issues associated with (1)
source of cells and (2) donation. The results could be divided into three clusters: Tissue, Donor, and Scientist.
Where the former two clusters roughly coincide with the results of the previous rounds, the third subject was
entirely new but discussed by both groups: the role of the scientist in the tissue engineering process.
Introduction
EuroSTEC is an integrated project on ‘‘Soft tissueengineering for congenital birth defects in children.’’
Funded by the European Commission under the Sixth Frame-
work Programme (FP6), it commenced on January 1, 2007. The
project unites 15 partner organizations (10 research institutes
and 5 companies) from nine European countries.1
Recent developments in tissue engineering will be used to
treat children with congenital structural disorders, such as
spina bifida, urogenital defects, gastroschisis, diaphragmatic
hernia, and esophageal atresia. The EuroSTEC project fo-
cuses on both maternal–fetal (or in utero) as well as neonatal
interventions using tissue-engineered products. Part of the
EuroSTEC project design is an extensive ethical analysis,
which will focus on all three phases of the project—(1) fun-
damental (in vitro) research, (2) animal experiments, and (3)
clinical trials—and will also look ahead to the application of
soft tissue engineering in clinical practice.
In a previous study we conducted a survey of ethical issues
that might arise during the course of the project.2 A modified
Delphi study—a systematic forecasting method consisting of
multiple rounds—was used to question professionals who are
directly involved in preclinical or clinical research on tissue
engineering for congenital birth defects. Their views on pos-
sible moral issues throughout the course of the project were
surveyed as a starting point. As is commonly done, we
modified the Delphi method and restricted the number of
rounds to ensure a high response rate throughout the multiple
rounds.3–5 The first two rounds yielded a number of ethical
issues2 that demanded further exploration.
For the fundamental research phase, two dominant cate-
gories of ethical issues emerged: ethical issues associated (1)
with the donation and (2) with the source of the cells used
(see Table 1 for a list of the ethical issues identified by Delphi
participants).
Previous literature research6 also identified these two
clusters of ethical issues for fundamental research in tissue
engineering. However, research on tissue engineers’ own
perspective on these issues was lacking. From the perspec-
tive of an empirically based ethics, the views of these
professionals—all involved in the EuroSTEC project—are
expressly relevant because they have practical experience in
the day-to-day routine of tissue engineering research and
carry responsibility for that practice. The central objective of
this empirical study was to further explore tissue engineering
experts’ views on the two topics.
Materials and Methods
Participants
Two groups of experts working in fundamental research
within the EuroSTEC project were formed, with attention
1Section Ethics, Philosophy, and History of Medicine, Scientific Institute for Quality of Healthcare, Radboud University Nijmegen Medical
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paid to equal distribution of gender, country, and place of
work (for group characteristics, see Table 2).
Focus group sessions
As a result of the first two rounds of the Delphi study, two
dominant categories were identified with regard to the fun-
damental research phase2: ‘‘donation’’ and ‘‘source of cells.’’
The first Delphi round focused on the identification of ethical
issues by the participants and round two asked them to in-
dicate the importance of the issues identified. The focus
groups in the third round aimed at exploring why these is-
sues were mentioned and deemed more or less important.
Focus groups are a form of group interview that uses com-
munication between research participants to its advantage in
order to generate research data; the group interaction during
the process is explicitly used as part of the method. The idea
behind the method is that a group process enables partici-
pants to explore and clarify their views in ways that would
be more difficult during a one on one interview.7
The sessions were held in April 2009. General methodol-
ogy and procedure were first explained in a plenary session,
after which both groups went to separate rooms. A hand out
with the ethical issues previously mentioned and ranked in
order of importance was distributed to the participants of
each specific group. As an opening question, the focus group
leader asked the focus group participants for their opinion
on the ranking of the ethical issues. The discussion was led
by two senior researchers (W.D. and P.v.d.B.) and lasted
approximately 1 h. The sessions were recorded with the
consent of the participants to allow qualitative analysis.
Analysis
The recordings were transcribed and entered into Atlas-ti
5.2. The transcripts were coded using a grounded theory
approach, in which the codes and codebook emerge from the
data (as opposed to previously formulated hypotheses which
are ‘‘tested’’ against data).8 The transcripts were coded by a
primary analyst (A.O.), whereas a secondary analyst (W.D.)
reviewed the transcripts with the assigned codes and the
code book. Codes were then grouped into themes (or ‘‘fam-
ilies’’), and subsequently grouped in clusters.
Results
The qualitative analysis yielded 58 codes, which were
grouped into eight themes and subsequently clustered in
three clusters: (1) Tissue (16 codes in two themes), (2) Donor
(22 codes in three themes), and (3) Scientist (20 codes in three
themes).
Cluster 1: Tissue
This cluster encompasses two themes: (a) Beginning of life
and (b) Source material (Fig. 1).
Beginning of life. The theme of beginning of life was
addressed in focus group 2 (discussing the source of cells).
The group agreed that the main question in judging the
moral acceptability of experimenting with certain cell types
centers on the question of ‘‘what do we consider life?’’
Within this context, the group mainly delved into the dif-
ferences in moral status of human embryonic stem cells
(hESCs) and fetal cells. In the literature on ethical issues in
tissue engineering, the use of hESCs is the ethical issue most
frequently discussed.6 Still, only one participant had moral
qualms about working with hESCs. That participant would
decline working with hESCs personally, but did not have
problems with others working with these cells.
Some participants referred to the use of hESCs as ‘‘killing a
life,’’ with one person explicitly referring to Catholic doctrine
on the topic, others held a different view. In the words of one
of the other participants: ‘‘[Y]ou can’t [say] that they die be-
cause they never lived.’’ Most of the participants seemed to
consider the use of fetal cells ethically more problematic, re-
ferring to the possibility of injuring a fetus when taking a
tissue sample. As one person put it: ‘‘[P]eople don’t necessarily
Table 2. Participant Characteristics
Focus group 1 donation
(n = 10)
Focus group 2 source of cells
(n = 11)
Gender (% male) 7 (70.0) 7 (63.6)
Working in country Austria 2 3




Place of work (%) University/hospital 7 (70.0) 8 (72.7)
Industry 3 (30.0) 3 (27.3)
Table 1. Ethical Issues in the Fundamental Research
Phase as Identified by Delphi Participants
Category Topic
Source The use of fetal cells
The use of cells from neonates
The use of fetal stem cells
The use of excess tissue obtained
through abortion
The use of embryonic stem cells
The use of umbilical cord stem cells
Donation Privacy of the donor of tissue
Informed consent of the donor of tissue
The possible invasiveness of the procedure
through which tissue is obtained
Unclarity about the ownership
of donated tissue
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think that embryonic stem cells [.] would have the possi-
bility of developing into an adult while fetal cells [.] come
from the fetus which can potentially survive to be something.’’
Another participant referred to a difference in views be-
tween scientists and the general public, citing that where a
scientist might view leftover embryos of in vitro fertilization
(IVF) as a mere clump of cells, the general public sees it as
new life and might judge their moral value differently.
Source material
The discussion of this theme overlapped with the previ-
ously discussed theme of the beginning of life. In discussing
the complex issues of different sources of tissue engineering
material, the deciding factor for most participants seemed to
be the consequences for the donor of the sampled tissue, not
necessarily the moral status of the source of the tissue. One of
the participants noted it was not actually the nature of the
cells that determined his moral judgment, but he instead
considered the consequences of the ‘‘harvesting’’ of the cells
in question the deciding factor in how ethically problematic
the use of this tissue would be. For example, according to
this argument cells that remained after IVF (‘‘leftover’’) were
less problematic than cells taken from a fetus, living in utero,
through biopsy. He argued that he would have to look at the
consequences (‘‘what I am endangering’’) to make a final
judgment on a case-by-case basis.
Cluster 2: Donor
This cluster was divided into three subthemes: (a) Control
over use, (b) Helping, and (c) Miscellaneous (Fig. 2).
Control over use. All participants deemed control, or
some say over their donated material, important for donors,
especially when the purpose of its use is considered. Ac-
cording to the participants, the donated material should not
be used for ‘‘bad’’ purposes without the donor’s knowing; if
a donor is told their material will be used for ‘‘good’’ re-
search, their material should indeed be used for the purpose
they were informed about and agreed to. As one participant
put it: ‘‘Let’s say if you agree to, with my donated tissue, to
help children in need [.] then you want to know that this
helped children in need. The specific child that is [.] helped
might not be that important to you, but it could be that,
okay, this is not for developing cosmetics for this cosmetics
industry.’’ Another said: ‘‘Suppose that the military would
[want] to use it, to see the effect of some kind of bomb or
whatever. I would definitely not like to have my skin be used
for that.’’
An added difficulty is the removal of tissue from incom-
petent subjects and their inability to give consent. Several
participants indicated that if they were to give proxy consent
for the use of tissue from their children, they would restrict
their consent solely to autologous use. Only when the child
in question would reach the age of consent the material
could be used for other purposes, and only if the child
agreed. One participant was quite adamant about the ques-
tion of ownership in this context: ‘‘This belongs to the child.
’Cause [.] for me there’s no question of ownership. There’s
a fingerprint on the material that has been donated [by] the
child. [I] as a parent just gave the opportunity [.] to donate,
but what has been donated is not my property, even though I
[gave] the permission.’’
Should donors be able to withdraw their consent? One
participant said that that would not be a problem, and he
would simply ‘‘go to [his] fridge, I would take his sample, I
would take his slides, I would [.] discard the data from my
Excel file and it’s done.’’ Others, however, saw this as a near
impossibility; for instance, what should be done if data have
already been published based on the material this person
donated?
The question of the extent to which a donor should and
can be informed about the future use of their donated sample
FIG. 1. Themes and codes for cluster ‘‘Tissue.’’
FIG. 2. Themes and codes for cluster ‘‘Donor.’’
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was thoroughly discussed. The way in which a scientist
frames the question might heavily influence the likelihood of
a prospective donor consenting. As one participant put it:
‘‘Are you willing to help people with cancer? Who wouldn’t
say yes to that question? But if they knew that this helping
people with cancer would really be taking the cells, isolating
the cells, cryopreserving them and multiplying them and
spreading them all over the world, maybe they wouldn’t be
so helpful.’’ Another participant added that it would be very
difficult to specify exactly what donated tissue would be
used for, because it often happens in tissue engineering, that
the exact purpose is still unknown when one takes the
sample.
Helping. Keeping in mind the difficulties that surround
the process of donation as discussed in the context of the
previous theme, the main motivation for donation was ad-
dressed: being able to help, be this helping oneself (in au-
tologous donation), helping others, or being of benefit to
science in general. In spite of possible obstacles or problems
involved in donation, all participants agreed altruism is re-
quired to keep the scientific process of tissue engineering
going. As one participant indicated, if there were no parents
who gave consent to use their child’s tissue, a large part of
the research of this very project could not be done.
Miscellaneous. In addition to the two broader themes
that were donor-related, several smaller topics received at-
tention.
The achievability of full anonymity, one of the staples of
the donating process, was questioned by the group; after all,
in order to do research on a sample, characteristics like
gender, race, and possible diseases are known to the re-
searcher, which means that the sample might be traceable to
a certain donor. Additionally, the balance between ano-
nymity/privacy on the one hand and the previously dis-
cussed control over tissue on the other was deemed
problematic. If one would be required to continue to supply
a donor with information about the purposes of the use of
parts of their material, then the repeated information re-
quires that name and contact information would have to be
known to someone, thereby encroaching on the ideal of an-
onymity and privacy.
In discussing possible motivations for donating, the topic
of financial compensation came up. Several participants were
adamant about their opposition to paid donation. One ex-
plained: ‘‘I would oppose it 100%. [.] It can induce all kinds
of strange situations [in which people] are trying to make
money if [they]’re poor, [.] doing things that are very un-
healthy. So to protect people from themselves, I would say, I
would oppose it.’’
Cluster 3: Scientist
The cluster ‘‘Scientist’’ consists of three themes: (a) Future
of science, (b) Scientist and society, and (c) Scientist as person
(Fig. 3).
Future of science. In discussing problems associated
with the (proxy) consent process, several participants pre-
dicted that a stricter, more rigorous process might cause the
number of parents that donate their children’s tissue to de-
crease. They conjectured a decrease in number of donated
tissues might seriously impede scientific progress. One par-
ticipant, a university teacher, used the analogy of using an-
imals to benefit human beings through research: ‘‘[N]ot
everyone understands the implications of not giving away
tissue samples for research. I would like to [use] the example
of my teaching where I say ‘animal trials’ and students stand
up and say ‘no, why do you use animals? [.] we’re totally
against the use of any animals for anything.’ And I say,
‘Okay, please sign this paper, we will not use any of the
treatments that have been developed using animals on you
and your family.’ They say, ‘‘Uh oh, no, no, I’m [in favor of]
animal.use of animals,’ so the implications of not being able
to use human tissue in research means that you don’t have a
cure for diseases and the coupling there is not maybe obvi-
ous for people. It’s not even obvious for my university stu-
dents.’’
Scientist and society. The relationship between a scien-
tist and society, especially the role of communication, was
discussed extensively. The risk of popular media picking up
wildly negative stories about certain technologies was
viewed by all as a real threat. According to the participants,
the influence of the media on popular opinion about tech-
nology should not be underestimated. Therefore, scientists
should tell the public about their work, although explaining
the details of the tissue engineering process to a largely lay
audience remains a challenge.
One participant described the responsibility of a scientist
as follows: ‘‘[S]cientists tend to only see the good side of stem
cell biology, and we often forget that there is a general public
which has an opinion about the consequences of different
research and scientists have a tendency to think; oh,
this.this works for this particular application while there’s a
huge amount of consequences that maybe we’re not thinking
about. [.] Before you jump on a new train you have to test
that it’s safe and that, for instance, if we use embryonic stem
cells there are all sort of different cancers and new diseases
FIG. 3. Themes and codes for cluster ‘‘Scientist.’’
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that can be introduced. Maybe not right away, but maybe in
50 years, and this is gonna be a new generation of kids that
we have helped survive, but that will develop terrible dis-
eases in the future. [.] So, I think it’s sort of why we’re
sitting here and discussing this because we need to be aware
that the general public has an opinion and we carry a very
strong responsibility to make sure that we sort of think twice
before we just.’’
Scientist as person. With the talk of bad research, public
mistrust and misinformation, one of the participants was
quick to add the following: ‘‘I think we should state again
that the researchers are, most of the researchers are on the
good side, and that they really want to develop treatments,
and that they do not want to create Frankensteins or make
money out of it and therefore it’s not such an ethical issue to
give the consent to use the tissue for research purposes, at
least in my view. [.] If it comes to companies that are using
the tissues, this is probably.or definitely different, and if it
comes to induced pluripotent stem cell lines that are being
created from differentiated cells that is also a different issue.
But if you do our standard work that we all do now, I think
we are still on the good side and we could even show the
donors or the people that gave the consent what has been
done with the tissue and in which direction the research is
going.’’
In talking about how they reached a moral judgment of a
certain act or technology, the participants indicated that
different personal factors influence their judgments of right
and wrong, and their willingness to work with certain mat-
ters or perform certain actions. One of these factors seemed
to be personal experience with a disease that was potentially
treatable with the technology at hand. This might make a
scientist more likely to judge the technology favorably. Other
factors mentioned included the way they were raised by
their parents, and possible religious influences. In the end,
participants seemed to view ethical judgments on the ac-
ceptability of a certain conduct or technology as incredibly
personal, as one person said: ‘‘[F]or me there’s no right or
wrong, if [other participant X] says her opinion, then her
opinion is as good as my opinion.’’
Discussion
On the basis of the results of two previous rounds of
questionnaires, two categories of issues were discussed in
two focus group discussions: donation and source of cells.
The results of the discussion were divided into three clusters:
Tissue, Donor, and Scientist. Where the former two roughly
coincide with the two groups of issues that were the result of
the previous Delphi rounds, a third, entirely new, subject
was discussed by both groups: the role of the scientist in the
tissue engineering process.
When comparing our results to discussions in the litera-
ture on the same topics, several similarities become apparent.
For instance, like our participants, articles that discuss in-
formed consent of tissue donors stress the importance of
thorough information about future use of their material9–19
and protecting the privacy of the donor through anonymi-
ty10,12–14,17–21 In our study, we learned of the difficulties that
would arise while striving for these ideals in practice, as they
were pointed out by our participants.
In surveying the arguments of the focus group partici-
pants, one matter is striking. Their way of arguing their case
is very personal and subjective: in answering a question,
their responses take the form of ‘‘if I were in that situation, I
would.’’ or ‘‘if that were my child, I..’’ Additionally,
participants’ answers generally display a consequentialist
manner of reasoning: in assessing a situation, the majority of
the participants look to the consequences of an act as the
criterion for deeming it morally right or wrong. One example
is the use of embryonic stem cells and the ensuing discussion
of what is considered human life. The ethical literature on the
topic generally argues the case in terms of principles (e.g.,
sanctity of life and human dignity).22–26 However, in these
focus groups, the discussion came down to the comparison
of different manners of obtaining tissue and their possible
negative consequences, with those consequences informing
the eventual moral judgment. A similar thing is apparent in
the discussion of paid donation. Where the literature, while
also discussing undesirable consequences, argues mostly in
terms of violating human dignity,18,27–32 the discussion in
our focus groups solely focused on the undesirable situations
paid donation might result in.
As is known from literature on teaching ethics, certain
tendencies are apparent when non-ethicists discuss ethics,
most notably skepticism (the belief that ethics has no right or
wrong answers) and subjectivism (the belief that ethics is
whatever any person feels is right).33,34 From time to time,
both are also noticeable in our participants’ reasoning. As
became apparent in the focus group discussions, the partic-
ipants seem very aware of their personal responsibilities both
toward the scientific community and society at large. How-
ever, to meet these responsibilities in the complex setting of
scientific research in research groups or competitive enter-
prises, skepticism and subjectivism are insufficient. Working
with a group of people toward a common goal, some sort of
intersubjective truth or norm is needed, one that transcends
mere personal opinion or preference. These ethical norms in
research help scientists to coordinate their actions and to
establish and maintain the public’s trust of the discipline.35
Because the focus groups were part of a larger Delphi
study and were preceded by two rounds of questionnaires,
the participants were familiar with each other and the study
in question. Therefore, during the focus group meetings
relatively little time was needed to familiarize the partici-
pants with the process, as a cognitive process had already
been set in motion.
Our population consisted of a diverse group of tissue
engineering professionals: participants were involved in
different types of fundamental research, and many different
countries, nationalities, occupations, and institutions were
represented. The views of tissue engineering experts outside
of the EuroSTEC project, as well as those of ethicists and
patients, were lacking from this study. To obtain an even
richer overview of the ethical aspects of tissue engineering, it
is our explicit intention to extend the target population of
future empirical research to include these other groups.
Ethics of tissue engineering and regenerative medicine is
still a relatively small field. This study is the first to feature
qualitative research concerning tissue engineering profes-
sionals’ views on ethical aspects of preclinical research in
tissue engineering. Although the participants in this study
were recruited from one specific project, the relevance of our
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results need not to be limited to this project. Numerous
parallels can be drawn between the project at hand and any
other preclinical study in the field of tissue engineering.
Therefore, we believe that our study will be of relevance to
fundamental research in tissue engineering in general.
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